Mechanistic insights into activation of peracetic acid by sludge biogas residue biochar for efficient sulfamethoxazole degradation in aqueous solution

Article

作者: Yang, Lie ; He, Xiaoman ; Wu, Li ; Huang, Min ; Chen, Xiaolong ; Li, Yulong ; Xue, Jianming

The application of peracetic acid (PAA) in the advanced oxidation process has been demonstrated to be an effective approach for treating aqueous organic pollutants. In this study, it is the first time that biogas residue biochar (BRBC) derived from sludge anaerobic digestion plants was prepared and used as a PAA activator for sulfamethoxazole (SMX) degradation. The optimal SMX removal could achieve 92 % within 120 min under acidic conditions. The SMX degradation was slightly enhanced in the presence of Cl^-, while it could be inhibited by HCO₃^-. Quenching experiment and EPR analysis demonstrated that both radical and non-radical processes contributed to SMX degradation. ECOSAR analysis showed a significant reduction in intermediate toxicity. Meanwhile, BRBC700 exhibited excellent reusability and stability even in real water matrices. The study presented an innovative approach for biogas residue application and provided a novel pretreatment for SMX-containing wastewater for further biological treatment method after simple acid-base regulation.

2024-12-01·WASTE MANAGEMENT

Sequential carbonization of pig manure biogas residue into engineered biochar for diethyl phthalate removal toward environmental sustainability

Article

作者: Lu, Haiying ; Zhou, Dongmei ; Xue, Jianming ; Ji, Rongting ; Wang, Min ; Cheng, Hu ; Zhu, Changyin ; Han, Jiangang ; Yuan, Xiangzhou

Manure biogas residue has attracted increasing attention in waste recycling but faces substantial challenges because of its low carbon content, high ash content, and high heavy metal content. A novel sequential carbonization approach was proposed for recycling biogas residue; this approach consisted of pre-pyrolysis, activation with Ca(OH)₂, and then activation with KOH. Pig manure-derived biogas residue was upcycled into engineered biochar (EB) with a high yield (26 %) and showed excellent performance in removing a typical plasticizer, diethyl phthalate (DEP). The proportion of carbon content greatly increased from 18 % (biogas residue) to 67 % (EB); however, the ash content decreased from 50 % (biogas residue) to 24 % (EB). The concentration of heavy metals decreased, and Zn had the largest decrease from 713 mg kg^-1 to 61 mg kg^-1 (p < 0.001). The sorption of DEP onto EB was rapid and reached equilibrium within 20 h. The developed specific surface area of EB was 1247 m²/g and provided abundant sorption sites for DEP; additionally, the sorption quantity reached 309 mg/g. The sorption capacity was dominated by surface adsorption. The oxygen-containing functional groups, graphene structure, porous structure, and hydrophobicity of EB contributed to the pore filling, hydrogen bonding, π-π stacking, and partitioning processes. Furthermore, the EB showed excellent practical application potential and great cycling stability. A sequential carbonization strategy was proposed to upcycle manure biogas residue into the EB for DEP removal; moreover, this strategy can aid in the attainment of environmental sustainability, including sustainable waste management and environmental pollution mitigation.

2024-12-01·SCIENCE OF THE TOTAL ENVIRONMENT

Capturing differences in the release potential of dissolved organic matter from biochar and hydrochar: Insights from component characterization and molecular identification

Article

作者: Xue, Jianming ; Cheng, Hu ; Ji, Rongting ; Wu, Yudong ; Zhu, Changyin ; Zhang, Longjiang ; Yang, Yiting ; Min, Ju ; Zhou, Dongmei ; Liu, Chenwei

Biochar and hydrochar have garnered widespread attention owing to their excellent performance in environmental remediation, carbon sequestration, and resource utilization from biowaste. Studies on the release potential of dissolved organic matter (DOM) have been limited, and the distinction between biochar and hydrochar remains unclear. In this study, pine sawdust was utilized as a model precursor with the aim of comparing the release quantity, components, and properties of DOM from biochar (BDOM) and hydrochar (HDOM) under various simulated conditions. The amount of DOM released by hydrochar (38.20-190.49 g/kg) was significantly greater than that released by biochar (0.57-11.96 g/kg), and more DOM was released at higher temperatures and pH values. BDOM consists of three categories of components, namely, humic-like, protein-like, and benzoic acid-like and tyrosine-like substances compounds, whereas HDOM consists of four categories of components, namely, two categories of humic-like compounds and two categories of protein-like compounds. By using ESI-FT-ICR-MS technology, 8586 compounds in BDOM and 6428 compounds in HDOM were identified. A total of 4665 unique compounds were found in BDOM, 1416 unique compounds were found in HDOM under alkaline release conditions, and HDOM contained more unique compounds than those found in other environments. CRAM/lignin-like compounds made up the majority of the released DOM and reached 31.01-65.35 % for BDOM and 54.79-73.05 % for HDOM. These findings revealed significant differences in the release potential of DOM from biochar and hydrochar, and further behavior research is needed to guide future applications of char materials in the environment and agriculture fields.

项与 New Zealand Forest Research Institute Ltd. 相关的新闻（医药）

2024-02-07

·药明康德

速递 | 开发潜在治愈性或革命性疗法，3.1亿美元助力构建卓越生物技术公司

▎药明康德内容团队编辑今日，Petrichor旗下的Scion Life Sciences公司宣布完成首支基金的募资，募资额超出预期，达到3.1亿美元。Scion Life Sciences公司致力于创建和培养专注于发现、开发和商业化革命性或潜在治愈性创新疗法的卓越生物技术公司。Scion由行业资深人士Samuel W. Hall博士和Aaron M. Kantoff先生，以及Petrichor的创始人和管理合伙人Tadd S. Wessel先生共同创立和领导。Scion的使命是为严重和威胁生命的疾病提供治愈性、或变革临床管理的药物。这一目标指导着公司的全部战略和运作方式。Scion将基于转化创新，构建具有正确构架的生物技术公司，将其转化为具有重要临床意义的药物。Scion将为其投资的公司提供长期资本和运营资源，以实现它们发现和开发的疗法的临床潜力。Scion可以进行最少数千美元的初期投资以支持早期孵化项目，并有能力在每个投资公司的生命周期中累计投入6000万美元以上的资金，从种子轮之前阶段一直支持有前景的公司直到IPO及以后。Scion公司采用严谨的投资方法，专注于三个核心支柱，以降低风险并最大化产生革命性疗法的可能性：投资于成熟的治疗模式和在现阶段或近期内能够产生重大医疗进步的赋能技术。瞄准那些对底层科学有深入理解、能够进行有力干预的治疗领域、疾病和药物靶点。关注能够由独立的生物技术公司有效解决的临床问题。Scion拥有一个经验丰富的科学、医学、金融、技术和运营专业人员团队。该公司已开始使用其首个基金进行投资，已有四个有前景的公司成立项目正在进行中。为了增强其能力，Scion还推出了Scion Innovations，这是一个致力于研发和运营支持的内部部门。该举措使Scion能够做出明智、客观的决策，确保只有最有潜力的项目才能发展成为投资组合中的完整公司。大家都在看药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies. Retrieved February 7, 2024, from https://www.prnewswire.com/news-releases/scion-life-sciences-launches-with-oversubscribed-310-million-fund-to-create-and-build-exceptional-biotech-companies-302055568.html免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

IPO临床研究基因疗法微生物疗法

2024-02-07

·PRNewswire

Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies

Scion debuts as a biotech company formation specialist, dedicated to creating clinically important medicines and with the right structure and resources to support its most promising portfolio companies through to maturity as late- or commercial-stage biopharmaceutical enterprises NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Scion Life Sciences ("Scion"), an affiliate of Petrichor, is a New York City-based life sciences venture capital firm dedicated to founding and building exceptional biotechnology companies that discover, develop, and seek to commercialize clinically transformational or curative new medicines, today announced the final close of its inaugural fund, which was oversubscribed with $310 million in capital commitments. Scion was founded and is led by longstanding partners and experienced company-builders and investors Samuel W. Hall, PhD, and Aaron M. Kantoff, together with Tadd S. Wessel, founder, and Managing Partner of Petrichor. Scion's mission is to create medicines that cure or transform the clinical management of serious and life-threatening diseases and this overriding objective informs every aspect of the firm's strategy and approach. Scion forms and builds companies around translational innovations with the right bone structure to become clinically important medicines and is structured to support portfolio companies with the long-term capital and operational resources required to realize the mature clinical potential of the therapies they discover and develop. Scion is able to make initial investments as small as a few thousand dollars in early-stage incubation efforts but is resourced to cumulatively deploy $60 million or more over the life of each portfolio company investment and to support promising portfolio companies from pre-seed stage through to IPO and beyond. Scion's strategic and pragmatic approach to investment and innovation is honed by experience, supported by historical industry data, and actualized through disciplined and scaled capital deployment. The firm leverages an asset selection strategy built on three investment pillars to mitigate risk and increase the probability of delivering transformational medicines for patients: Invest in therapeutic modalities and enabling technologies that are sufficiently mature to make clinically important medicines today or in the near term Invest in therapeutic areas, diseases, and drug targets where deep understanding of the underlying science makes powerful intervention possible Focus on clinical problems that can be addressed with the resources available to an independent biotechnology company "We believe that solving clinically important problems is the fundamental driver of value creation in the life sciences industry and that sustained, long-term support is critical to building companies capable of generating these solutions," said Sam Hall, PhD, co-founder, and Managing Partner of Scion Life Sciences. "These convictions determine where we invest our capital and human resources and how we build our portfolio companies." Scion has established an experienced team of scientific, medical, financial, technological, and operational leaders that enable an active approach to founding and building companies and to create or refine innovative therapeutic substrate internally. The Scion team has begun investing its inaugural fund with four promising company formation efforts underway. Details of the fund's growing portfolio will be disclosed subsequently as ongoing company builds mature and additional efforts are initiated. To further enhance capabilities, the team also established Scion Innovations to provide in-house R&D capabilities and operational resources. This equips Scion with the information and technology to make efficient, objective decisions and helps to ensure that only programs with exceptional potential mature into full-scale portfolio company investments. "We build companies with the primary objective of creating important new medicines, not exits," added Aaron Kantoff, co-founder, and Managing Partner of Scion Life Sciences. "Our proactive and data-driven approach to company building allows us to generate a concentrated portfolio of best ideas, optimized to yield real medicines that change the lives of patients and caregivers. This objective, along with our long duration fund structure, enable us to build sustainably operating biotechnology companies, that are capable of ascending to valuations in the tens of billions as they commercialize clinically transformational new medicines." "We appreciate the trust of our limited partners that share the Scion team's conviction in the profound economic and societal value creation potential of clinically important new medicines," said Tadd Wessel, co-founder, and Managing Partner of Scion Life Sciences and Petrichor. "Sam and Aaron have established themselves as exceptional investors and company builders and the outlier success of the companies they have previously built together provides impressive validation of their unique approach. I and the entire Petrichor team are delighted to partner with them in building Scion." About Scion Life Sciences Scion Life Sciences, an affiliate of Petrichor, is a life sciences venture capital firm committed to meaningfully improving human health through long-term ownership of clinically transformative therapies. Our team of experienced innovators, company-builders and investors is founding and building exceptional biotechnology companies to discover, develop, and commercialize clinically transformational or curative new medicines. We aim to support impactful and sustainable advancements with a strategic and pragmatic approach to investment and innovation. For more information, please visit . About Petrichor Petrichor partners with world-class healthcare managers and businesses to provide customized investment structures and support. The Petrichor team has completed over 125 investments representing more than $6 billion in invested capital and has held over 55 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies. For more information, please visit . About the Scion Life Sciences Leadership Samuel W. Hall, PhD Sam is a founder and Managing Partner of Scion. He has more than 20 years of experience in the life sciences across roles as an investor, scientist, and entrepreneur. From 2013 until October 2019, Sam was a Partner at Apple Tree Partners (ATP), where he focused on creating and building therapeutics companies. During his tenure at ATP, Sam contributed to the formation, financing and build-out of Syntimmune (acquired by Alexion Pharmaceuticals), Stoke Therapeutics, Chinook Therapeutics (acquired by Novartis), Marengo Therapeutics and Ascidian Therapeutics and served as a member of each company's Board of Directors. Prior to joining ATP, Sam was an immunologist at the University of Cambridge. Prior to returning to academia, Sam was a member of the investment team at Symphony Capital and began his career as an investment banker at Citigroup. Aaron M. Kantoff Aaron is a founder and Managing Partner of Scion. He has spent over a decade specializing in founding, building, and investing in life sciences companies, focusing primarily on therapeutics. Aaron currently serves as a board member of Tourmaline Bio, where he has been serving since the company's inception. Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC and assisted the team with other privately-held therapeutics investments. Before joining Medicxi, he was a co-founder and board member of RayzeBio, which was recently acquired by Bristol Myers Squibb. From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a New York-based life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment practice, playing a leading role in assembling several ATP portfolio companies, and most notably, serving on the boards of Akero Therapeutics, Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately-held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics. Tadd S. Wessel Tadd is the founder and Managing Partner of Petrichor, a private investment firm focused on the healthcare sector. He is also a founder and Managing Partner of Scion. Tadd has more than 25 years of healthcare finance experience, primarily focused on the life sciences sectors. Previously, he was a Partner at OrbiMed Advisors, where he led the build-out of the structured investment business. Prior to OrbiMed, Tadd was a Vice President at Fortress Investment Group focused on healthcare investments. Tadd has served on more than 30 boards most recently including Aurion Biotech, Cryoport, and ITM. He also serves on the Advisory Board of the AIM at Melanoma Foundation, whose mission is dedicated to finding more effective treatments and, ultimately, the cure for melanoma. He also serves on the Board of the International Centers for Precision Oncology (ICPO) whose mission is to scale access of molecularly targeted precision oncology diagnostics and therapeutics for the benefit of cancer patients globally. SOURCE Scion Life Sciences

2024-02-07

·FierceBiotech

2 former Apple Tree investors roll toward new biotech-focused fund launching with $310M

Scion co-founders Sam Hall, Ph.D., and Aaron Kantoff were colleagues for six years at Apple Tree Partners until 2019. Two former Apple Tree investors have set off on their own path, blossoming a new biotech-focused incubator with an inaugural fund of $310 million. Scion Life Sciences officially hit the stage Tuesday morning, led by Sam Hall, Ph.D., and Aaron Kantoff, who overlapped at VC firm Apple Tree Partners for six years until 2019. Kantoff, co-founder of Bristol Myers Squibb-bought RayzeBio, also spent some time as a venture partner at European investment firm Medicxi before starting Scion. Scion’s core mission is not too different from many other biotech investors, with an emphasis on directing capital to scientists and research that have a high probability of success and could result in paradigm-shifting medicines. To accomplish that, Scion and its founders are laying out a concise road map that starts with incubating early science focused on biologics and large-molecule development. The firm’s in-house R&D capabilities, dubbed Scion Innovations, will be used as a proving ground for scientists and entrepreneurs looking to establish their first programs. Scion said in its announcement that “only programs with exceptional potential mature into full-scale portfolio company investments.” “We really want to be ruthless early in the incubation of the projects and companies we build,” Hall told Fierce Biotech in an interview alongside Kantoff. “We want to address head-on all of the key existential risks that we see that … confront the project and company build,” Hall added. The reason the fund is prioritizing large-molecule and biologics development is that this space spans some of the most mature science, according to the founders. Scion has “four promising company formation efforts underway,” as noted in a press release, which Kantoff elaborated span bispecific antibodies, conjugates, and gene and cell therapy. None of the potential companies are working on cancer treatments. Kantoff expects at least one of the four companies currently being incubated to launch before the end of the year, with another possibly on the cards as well. The effort to grow those biotechs so far has happened in parallel with fundraising efforts, which went as well as Kantoff and Hall could have imagined. They set out to raise $250 million with a hard cap of $300 million, but, thanks to “the tremendous amount of interest and momentum,” according to Kantoff, the investor syndicate agreed to raise the cap to $310 million. The firm is affiliated with healthcare private equity company Petrichor, although Scion’s founders insist the two will operate separately. Hall described the two entities as “separate businesses with partners in common,” with a relationship principally focused on shares administrative functions. Tadd Wessel, Petrichor’s managing director, is a co-founder and managing director of Scion. “I and the entire Petrichor team are delighted to partner with them in building Scion,” Wessel said in Scion's release. Editor's note: This story was updated to correct that Petrichor and Scion do not have a tax partnership. The author misheard "Tadd's partnership" in the interview.